Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q1 2025 Earnings Presentation

11 slides from Surgical Science Sweden Ab's earnings presentation, May 14, 2025

  1. Slide 1: Presentation of Interim Report Q1

    Presentation of Interim Report Q1 May 14th 2025 ©2025 Surgical Science. | All rights reserved.

  2. Slide 2: CEO comments – Q1

    CEO comments – Q1  Solid topline growth of 30% excl. currency effects  Intelligent Ultrasound welcomed into Surgical Science  Revenue bounce back in Educational Products of 55% (32% excl. Intelligent Ultrasound), despite more challenging market climate  All-time-high license revenues (SEKm 84, +

  3. Slide 3: Updated financial goals

    Updated financial goals The sales target:  As a result of primarily slower development in the Robotics segment, and the current global trade uncertainties, where direct and indirect effects are very difficult to forecast, the company's Board of Directors and management have revised the sales target

  4. Slide 4: Q1: Strong growth despite macroeconomic uncertainties

    Q1: Strong growth despite macroeconomic uncertainties SEKm Q1:  Net sales was up 33% to SEKm 250.7 (188.2). In local currencies 30%. SEKm 18.3 from IU.  Educational Products’ sales up 55%. (32% excl IU). Sales increase: EMEA (+267%), Asia (+58%), Americas (+14%).  Industry/OEM was up 17%. License

  5. Slide 5: REVENUE STREAMS – ATH license revenues

    REVENUE STREAMS – ATH license revenues SEKm  License rev’s: 33 (34) percent of total revenues. Lumpy for new entrants, revenues from several customers.  Simulator sales up 47% vs Q1 2024.  Development rev’s higher. Consist of both robotics projects and sales of simulators w/in Indu.  Service rev

  6. Slide 6: COSTS AND EBIT MARGIN Q1 2025 – one-time costs

    COSTS AND EBIT MARGIN Q1 2025 – one-time costs  Gross margin 69% (66). Decreased share of license revenues (33 vs 34%) had a negative effect. Weak sales Q1 2024 meant higher fixed costs per simulator. Consolidation of IU affected gross margin negatively by Cost of goods sold 31% (34) ~2 percentage

  7. Slide 7: ORGANIZATION No of employees at end of period: (265)

    ORGANIZATION No of employees at end of period: 336 (265) Men 233 (191) Women 103 (74) Israel 146 (136) Sweden 70 (58) Market presence >90 countries USA 63 (56) UK 39 (1) Other 18 (14) * Offices / Development sites * Other: Primarily Germany and China. ©2025 Surgical Science. | All rights reserved.

  8. Slide 8: ADJUSTED EBIT

    ADJUSTED EBIT Q1: SEKm 250 50%  Adjusted EBIT excl. 45% acquisition & restructuring 200 40% costs SEKm 56.6 (26.0), 23% 35% (17). 150 30% 25% 20%  Reported adjusted EBIT 100 15% SEKm 30.1. 50 10% 5% 0 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2023 2024 2025 The chart is excluding acquisition as well as restru

  9. Slide 9: FINANCE NET AND TAXES

    FINANCE NET AND TAXES  Finance net for the quarter was SEKm 22.3 (1.9). Interest on bank balances, cost and hedge GBP loan, revaluation of internal loans towards subsidiaries and IFRS 16 effect.  Tax expense for the quarter was SEKm 13.0 (4.1).  Net result for the quarter was SEKm 33.2 (23.8). ©2

  10. Slide 10: CASH FLOW

    CASH FLOW SEKm 800 50%  Cash flow from operating activities SEKm -5.0 45% (28.5). Large tax payments during the q and 700 40% payment of acquisition costs. Change in working 600 capital SEKm -34.1 (-14.1 ). Inventory and A/R 35% increased somewhat, but marginally in constant 500 30% currencies. Lar

  11. Slide 11: Thank you

    Thank you Find out more at: www.surgicalscience.com Tom Englund, CEO tom.englund@surgicalscience.com Anna Ahlberg, CFO anna.ahlberg@surgicalscience.com ©2025 Surgical Science. | All rights reserved.

Surgical Science Sweden — Q1 2025 Earnings Presentation on 6ix